Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
3.340
+0.025 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 16, 2022
Via
Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 06, 2022
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
December 06, 2022
Via
Investor Brand Network
Exposures
Product Safety
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
December 06, 2022
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...
Via
Benzinga
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
December 06, 2022
From
Vistagen
Via
Business Wire
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 30, 2022
From
Vistagen
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 29, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 23, 2022
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
November 17, 2022
Via
Investor Brand Network
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 17, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
November 11, 2022
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 10, 2022
From
Vistagen
Via
Business Wire
Earnings Scheduled For November 10, 2022
November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter.
Via
Benzinga
Earnings Outlook For VistaGen Therapeutics
November 09, 2022
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
November 04, 2022
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 04, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
November 03, 2022
Via
Investor Brand Network
Vistagen to Present at Stifel 2022 Healthcare Conference
November 03, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Virtual Roundtable on Innovative Approaches to Mental Health Treatment
October 26, 2022
Via
Investor Brand Network
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
October 26, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment
October 20, 2022
Via
Investor Brand Network
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
October 19, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Shares Shareholder Voting Recommendations from Leading Proxy Advisory Firms
October 06, 2022
Via
Investor Brand Network
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
October 06, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference
October 03, 2022
Via
Investor Brand Network
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
October 03, 2022
From
Vistagen
Via
Business Wire
Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket
September 21, 2022
Gainers Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.